RUNX1 and pulmonary arterial hypertension: However, there is strong and accruing evidence to support the pathogenic role of SOX17 and RUNX1 in PAH and the potential of targeting the SOX17 and RUNX1 axis as a novel therapeutic approach in the management of PAH.